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There is no doubt that governments have a moral and legal responsibility to prevent the spread of 
HIV among prisoners and prison staff and to care for those infected.   They also have a 
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responsibility to prevent the spread of HIV among communities. Prisoners are the community. They 
come from the community, they return to it. Protection of prisoners is protection of our 
communities.1 
Joint United Nations Programme on HIV/AIDS 
(UNAIDS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IPRT/MQI Summary Findings 
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on HIV/AIDS & Hepatitis C in Irish Prisons 
• The rate of HIV infection among Irish prisoners is more than ten times higher than that in 
general Irish population. 
• The rate of hepatitis C infection among Irish prisoners is more than 100 times higher than 
that in general Irish population. 
• Rates of hepatitis C infection among women prisoners are as high as 50%. 
• High risk behaviours for the sexual and intravenous transmission of HIV and hepatitis C are 
wide spread in Irish prisons. 
• The Irish Prisons Service’s provision of HIV and hepatitis C prevention measures falls far 
short of the best practice models in other European and North American jurisdictions. 
• The Irish Prisons Service’s provision of health care services results in inconsistent and 
inadequate access to care for prisoners living with HIV/AIDS and/or hepatitis C. 
• In total, the current response of the Irish Prisons Service to the HIV and hepatitis C crisis 
falls far short of the Service’s stated objective, “[T]o provide primary health care 
(prevention, treatment and health rehabilitation) to offenders of at least an equivalent 
standard to that available to citizens in the general community.”2 
• The current response of the Irish Prisons Service to HIV/AIDS and hepatitis C falls far short 
of guidelines set out by the World Health Organization and UNAIDS, and is in violation of 
the spirit of Article 35 of the Charter of Fundamental Rights of the European Union. 
 
 
 
 
 
 
 
 
 
 
 
IPRT/MQI Summary Recommendations 
on HIV/AIDS & Hepatitis C in Irish Prisons 
Prisoners’ Rights 
• Prisoners have the right to protect themselves from HIV and hepatitis C infection. 
• Prisoners have the right to informed consent in regards to medical treatments, including the 
right to refuse treatment. 
• Prisoners have a right to confidentiality regarding their HIV and hepatitis C status. 
• Prisoners have the right to informed consent in regards to HIV and hepatitis C testing, 
including the right to refuse testing. 
• No prisoner should be segregated based upon HIV or hepatitis C status. 
• No one should be allowed to die in prison from HIV/AIDS or hepatitis C. 
Recommendations: 
• We recommend that the full range of harm reduction materials and initiatives including 
injecting equipment, sterilising facilities, condoms and sharps bins be made available to all 
prisoners. 
• We recommend that methadone treatment be available to those already on methadone 
programmes prior to imprisonment, and to those who wish to begin treatment while in prison. 
• Comprehensive education and training on drug use, HIV/AIDS, and Hepatitis C should be 
provided for all staff and prisoners across the country. 
• Doctors and other health care staff should be available on a full time basis in larger prisons. 
• Prisoners living with HIV/AIDS and/or hepatitis C must have access to proper and sufficient 
nutrition, including vitamin supplements and supplement drinks. 
• Compassionate release provisions for prisoners living with HIV/AIDS and/or hepatitis C 
should be exercised proactively, and earlier in the course of disease progression. 
• All necessary treatments including pain management should be made available in a non-
discriminatory and non-stigmatising manner. 
• Confidential HIV and hepatitis C testing must be made easily accessible for all prisoners. 
Pre- and post-test counselling must be a mandatory component of HIV and hepatitis C 
testing. 
 
 
BACKGROUND 
The 
Invisible 
Epidemic  
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HIV and hepatitis C infection rates in Irish prisons have reached 
epidemic levels. HIV infection rates amongst incarcerated people 
are more than ten times higher that in the outside population. Rates 
of hepatitis C infection, another chronic and potentially fatal 
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her.3 blood-borne disease, are more than 100 times hig
Studies have repeatedly shown that high risk behaviours for the transmission of the HIV and 
hepatitis C viruses not only occur in Irish prisons, they are in fact common. When coupled with the 
inadequacy of current prison health policies and programmes, this situation creates an environment 
where prisoners live in conditions of increased vulnerability to HIV and hepatitis C infection, and 
increased vulnerability to HIV and hepatitis C related health decline. This is not merely an issue of 
prison health concern. It is an issue with significant public health consequences. 
Ireland is not alone in this situation. Many countries are struggling with similar prison health crises. 
However, while rates of HIV and hepatitis C infection in Irish prisons are the same or higher than 
those of other western countries, our government’s response falls far short of the innovative 
measures adopted in many other states. In Ireland, effective measures for HIV and hepatitis C 
prevention are not available to prisoners. Medical services remain inadequate or inconsistently 
accessible. Irish prison health policy lags far behind current best practice, despite the fact that the 
measures necessary to address this crisis in a progressive and comprehensive fashion are not only 
known, they are already running effectively in prisons in other jurisdictions. 
Although prison health issues are often invisible to the public at large, the health of prisoners is in 
fact an important issue of public health concern. Everyone in the prison environment – whether   
they are prisoners, prison staff, or family members – benefits from enhancing the health of 
prisoners, and reducing the incidence of disease. At the same time, the high degree of mobility 
between prison and community means that any illnesses or health conditions developed or 
exacerbated in prison do not stay there. When individuals are released from jail, prison health issues 
necessarily become community health issues. For these reasons, the issue of HIV/AIDS and 
hepatitis C in prisons demands immediate action from community and government alike. 
The extent of the crisis – HIV and hepatitis C among Irish prisoners. 
• A 1997 study of 108 prisoners in Mountjoy found that 9% were known to be HIV positive. 
This figure was considered a low estimate as half the study participants had never received an 
HIV test, or were waiting for their results to be processed.4 
• A 1999 study of 1,200 incarcerated men and women found an overall HIV infection rate of 
2% and a hepatitis C infection rate of 37%. This same study found that nearly half of the 
incarcerated women tested were infected with hepatitis C.5 
• A 2000 study of 600 committal prisoners found an overall HIV infection rate of 2% and 
hepatitis C infection rate of nearly 22%.6 Among women prisoners, the HIV seroprevalence 
rate was nearly 10%, and the hepatitis C infection rate was 56%.7 
Rates of both HIV and of hepatitis C infection in the general Irish population are estimated to be 
0.1%8 These figures therefore reflect an HIV infection rate among prisoners more than ten times 
greater than that in the outside population, and a hepatitis C infection rate more than 100 times 
higher than the outside population. 
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HIV and hepatitis C are blood borne viruses. Both viruses are 
transmitted in similar ways, and both can cause chronic illness or 
death. While drug therapies exist that can help treat people living 
with HIV or hepatitis C infections, there is currently no cure or 
vaccine for either. 
Human Immunodeficiency Virus (HIV) 
The human immunodeficiency virus, commonly known as HIV, is 
the virus linked to AIDS.  HIV weakens and eventually destroys the body’s immune system – the 
system enabling the body to fight off disease and infection. When a person’s immune system 
becomes severely compromised, making them vulnerable to opportunistic infections that take 
advantage of the host’s weakened defences, they are diagnosed with acquired immune deficiency 
syndrome, or AIDS. These opportunistic infections, many of which are harmless to those with 
healthy immune systems, have the ability to incapacitate or even kill people living with HIV or 
AIDS. Most, if not all, people infected with HIV will go on to develop AIDS.9 
BACKGROUND 
HIV/AIDS 
& Hepatitis 
Common HIV related symptoms include chronic fatigue, diarrhoea, fever, mental changes such as 
memory loss, weight loss, persistent cough, severe recurrent skin rashes, herpes and mouth 
infections, and swelling of the lymph nodes. Opportunistic infections such as cancers, meningitis, 
pneumonia and tuberculosis are also common as an individual’s immune system weakens.10 
The primary routes of transmission for HIV are through unprotected sexual intercourse (anal or 
vaginal) with a person living with HIV/AIDS, the sharing of injection equipment or skin piercing 
equipment contaminated with HIV, and mother to child transmission during pregnancy, labour, and 
delivery, or as the result of breast-feeding. There is also a risk of transmission via blood transfusion 
or the use of blood products not screened for the presence of HIV.11 
HIV infection can be detected by a blood test. The test detects the presence of HIV antibodies (the 
reaction of the body’s immune system to the presence of the virus) rather than the HIV virus itself. 
The body typically takes six weeks to three months to produce sufficient antibodies to be detected 
by the test. For this reason, there is a window period in current HIV testing technology between the 
time a person contracts HIV and when he or she will register a positive test result. During this 
window period, it is possible that a person infected with HIV may register a false HIV negative 
test.12 
While treatment options for people living with HIV/AIDS have improved in recent years, there is 
still no cure for the disease. New combination therapies, or drug cocktails, have been successful in 
improving the health of many. Combination therapy involves taking three or four different 
medications at the same time. When effective, combination therapies can strengthen the immune 
system by suppressing the spread of HIV in the body.13 While combination therapy has proven a 
major breakthrough in HIV/AIDS care, it is not a cure, nor is it effective for everyone. 
Drug compliance is a key issue for people taking HIV combination therapies, as missed doses or 
interruptions in treatment can cause the suppressed HIV to begin spreading again.14 If many doses 
are missed, or if medications are taken sporadically, it is possible for the patient to develop 
resistance to the therapy, thereby negating its future efficacy.15 Diet can also be important in proper 
compliance, and some HIV medications are prescribed with specific dietary and mealtimes 
requirements in order to increase drug absorption, or reduce side effects.16 
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Many HIV medications cause significant and unpleasant side effects for the patient, including 
headaches, nausea, diarrhoea, and changes in body shape.17 Some HIV therapies are particularly 
damaging to the liver, which can cause serious concerns for people co-infected with both HIV and 
hepatitis C, a virus that attacks the liver. 
Many people living with HIV/AIDS also suffer from chronic pain. This pain can vary from 
occasional and mild, to constant and debilitating, depending upon the person, the stage of their 
disease, and their care setting. It is estimated that 30—80% of people living with HIV/AIDS suffer 
from pain related to their disease.18 In some cases, painful conditions can be exacerbated by the side 
effects of HIV medications. As a result, many people living with HIV/AIDS require pain 
management medications in addition to HIV therapies, including the use of opioids to treat severe 
pain. However, access to adequate pain medication can prove problematic. Studies have shown that 
people reporting moderate to severe pain are more likely to have their pain underestimated by 
doctors.19 Studies have also found that a patient’s sex, educational level, and history of injection 
drug use can be a factor in physicians’ undertreating of pain in people living with HIV/AIDS.20 
Discrimination of this type can create particular barriers for prisoners. 
The rate of HIV seroprevalence in Ireland as a whole is estimated at 0.1%.21 
Hepatitis C Virus 
Hepatitis C is a viral infection that affects the liver, and is known to be a major cause of chronic 
liver disease. 
Common symptoms of Hepatitis C infection include chronic fatigue, muscle and joint pain, and 
headaches. People living with Hepatitis C infection may also suffer nausea, skin rashes, and weight 
loss.22 Approximately 80% of people infected with hepatitis C will go on to develop chronic 
infection, which can lead to cirrhosis and liver cancer. Approximately 10—20% of people with 
chronic hepatitis C infection will develop cirrhosis. Over time, 1—5% of people with chronic 
infection will develop liver cancer.23 
Like HIV, hepatitis C is a virus that lives in the blood. It is primarily spread via blood to blood 
contact, particularly through sharing of contaminated injection equipment and skin piercing 
equipment. In Ireland, sharing syringes is the most common mode of hepatitis C transmission.24 
Sexual and perinatal transmission of hepatitis C are also possible, although less frequent. There is 
also a risk of infection through blood transfusion or use of blood products not screened for hepatitis 
C.25 
While the HIV virus lives for only a short time outside the body, it has been reported that the 
hepatitis C virus can survive for days, if not longer.26 For this reason, the risks of transmitting 
hepatitis C through practices such as body piercing and tattooing are high.27 The sharing of personal 
hygiene implements such as razors, toothbrushes, and nail clippers also presents a risk of hepatitis C 
transmission.28 
Hepatitis C infection can be detected through a blood test. As is the case with HIV, the test for 
hepatitis C detects the presence of antibodies in the bloodstream, rather than the virus itself. The 
body typically takes five weeks to three months for hepatitis C antibodies to be produced in 
sufficient quantity to be detected by the test. For this reason, a window period exists in between the 
time a person contracts hepatitis C and the time the test will detect their infection.29 During this 
window period, it is possible that a person infected with hepatitis C may register a false negative 
test result. 
 
 
 
 
 9
There is no cure for hepatitis C infection. The primary drugs used to treat hepatitis C are interferon 
and ribavirin, which are either taken alone or in combination. These therapies suppress the virus. 
They do not eliminate it.30 Treatment with interferon alone is effective in approximately 10—20% 
of patients. Interferon and ribavirin used in combination is effective in approximately 30—50% of 
patients.31 
The rate of hepatitis C seroprevalence in Ireland as a whole is estimated at 0.1%.32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BACKGROUND 
High Risk 
Behaviours in
Prisons 
Research in Ireland has consistently demonstrated that high risk 
behaviours for the transmission of HIV and hepatitis C – 
unprotected sexual intercourse, or sharing needles for activities 
such as injection drug use and tattooing – are wide spread among 
prisoners. Because this high risk behaviour takes place in an 
environment characterised by disproportionately high levels of 
HIV and hepatitis C infection, and a near complete lack of 
effective prevention measures, there exists a significant risk of 
transmission of these blood-borne diseases. 
Injection Drug Use in Irish Prisons 
• A 1997 study found that 1 in 3 prisoners had injected while incarcerated, with 84% of this 
group sharing injection equipment in prison. 1 in 4 of the injection drug users who bad been 
tested for HIV came back with positive test results,33 
• A 1999 study found that more than 40% of prisoners reported injecting at least once in their 
lives. 1 in 5 injection drug users stated that they first injected inside prison. Almost half of 
injection drug users reported injecting while incarcerated, and nearly three in five reported 
sharing injecting equipment in prison. The study found that 87% of those who had shared 
injection equipment in prison tested positive for hepatitis C.34 
• A 2000 study found that more than one-quarter of committal prisoners had injected drugs in 
their lives. Of those identifying themselves as past or current injection drug users, nearly 1 in 
5 first injected in prison, and 2 in 5 admitted to sharing injection equipment while 
incarcerated. The study found that 90% of injection drug users who had shared injection 
equipment in prison tested positive for hepatitis C.35 
• A 2000 study by Merchants Quay Ireland showed that 51% of the clients using their needle 
exchange programme had been in prison at some point. Of those who had been in prison, 
more than 2 in 5 reported injecting drugs while incarcerated. The study found that 70% of 
these injection drug user shared injecting equipment while in prison.36 
Sexual Activity in Irish Prisons 
• A 1999 study “found evidence of sexual contact between men in prison and an association 
between both hepatitis b and HIV infection and sex between men.”37 Approximately 2% of 
the men surveyed admitted to having anal sex with men while incarcerated.38 HIV infection 
rates among this group were found to be greater than 1 in 10.39 A related study in 2000 
found that approximately 1 in 100 male committal prisoners admitted to having anal sex with 
other men in prison. However, to underscore the conservative nature of this finding, the 
authors noted that questions on same-sex sexual activity “were the least likely to have been 
answered truthfully” by the study participants.40 We may therefore assume that the true level 
of sexual activity is higher. 
Tattooing in Irish Prisons 
• Tattooing is a very popular art form among prisoners, and there are many talented tattoo 
artists incarcerated in Irish prisons. Tattooing has also been identified as a risk factor for 
hepatitis C transmission in prisons.41 In Ireland, a 2000 study found that almost half of the 
prisoners they surveyed were tattooed, and that a quarter of those (nearly 15% of overall 
study participants) had received a tattoo while incarcerated.42 The researchers concluded 
‘“hepatitis C was more common in those with a tattoo than those without a tattoo”. They also 
concluded that those who had been tattooed in prison were more likely to test hepatitis C 
positive than those who were tattooed outside of prison.43 
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Irish research consistently and clearly shows that HIV and hepatitis C infection rates are 
significantly higher among prisoners than non-prisoners, and that high risk behaviour is 
commonplace behind bars. The question that must be asked is what steps will the Irish Prison 
Service take to ensure the health of prisoners, and the public at large? 
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Traditionally, concerns about disease transmission through 
injection drug use have been met with calls to further entrench 
the ethos and practice of “zero tolerance”. Increased penalties for 
drug use, tightened security measures to reduce the supply of 
drugs, and heightened surveillance of individual drug users are 
often put forward as simple ‘law and order” solutions to complex 
public health questions. However, such punitive responses alone 
can never address the issue of HIV and hepatitis C transmission. 
While such suggestions may be well intentioned – and are certainly politically expedient – they 
ignore the larger economic and social realities that drive drug use, drug trafficking, and disease 
transmission, and in doing so ensure that rates of infection will continue to climb. 
HARM 
REDUCTION 
A Framework 
for Change 
In recent years, many countries, including Ireland, have recognised the limitations of a strictly zero-
tolerance approach to drug use, and have implemented community health programmes that enable 
injection drug users to reduce their risk of contracting HIV and hepatitis C while continuing to use 
illegal drugs. These harm reduction initiatives – such as needle exchange programmes – have been 
enacted as a pragmatic response to injection drug use, and the attendant risks that HIV and hepatitis 
C infection pose to the individual and society as a whole. 
While harm reduction policies do not condone illegal drug use, they do recognise that reducing the 
transmission of blood borne diseases in society is a more urgent and achievable goal than is ending 
drug use. As drug users are often isolated from mainstream health services, harm reduction 
initiatives such as needle exchanges and methadone maintenance programmes also create important 
links between health professionals and these marginalized communities, thus enabling drug users to 
maintain and improve their health. 
Ireland’s National Drug Strategy. 2001—2008 endorses the principles of harm reduction in the 
development of a comprehensive approach to drug use and disease prevention in the community. It 
states, 
Traditionally, the dominant trend in policy has been towards the...ultimate attainment of a 
drug free society. However, the recognised link between drug misuse and the spread of 
diseases has resulted in the need to adopt strategies that reduce the risk posed by such 
behaviour both to the individual misuser and the wider community.44 
As a result, the National Drug Strategy identifies the expansion of needle exchange and methadone 
maintenance programmes as key components of its action plan. 
While the government has recognised the value of harm reduction programmes, and supported their 
implementation in the general community, they have made no parallel effort to extend the 
availability of these programmes to prisoners. Yet drug use and drug trafficking are as much a part 
of prison life as they are a part of Irish society. The secure environment of the prison does not alter 
this reality, in Ireland or anywhere else. In fact, studies have shown that the particularities of the 
prison environment lead many prisoners to use injection drugs for the first time while incarcerated, 
or to choose injection over other methods of ingestion.45 
Given these facts, we must ask on what basis can the state continue to delay or deny the 
implementation of comprehensive harm reduction programmes in prisons? This question is even 
more resonant given the success of harm reduction initiatives in prisons in other parts of Europe. 
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Despite their illegality, the penalties for their use, and the significant amounts of money and person 
hours spent by the Prisons Service to stop their entry, the fact remains that drugs get into prisons, 
and prisoners use them. Just as in the broader society, drugs get in because there is a market for 
them, and because there is money to be made by providing them. This simple truth continues to 
drive drug availability in prisons, and drug availability in Ireland overall. The government must be 
realistic about this fact, and act pragmatically and effectively to reduce this risk to individual and 
public health. Rather than focusing solely on the question of ‘‘How do we stop drugs getting into 
prisons?” the government must face up to the bigger question of “How do we minimise the 
individual and societal health risks resulting from drug use?” The government has taken important 
steps in this regard in the outside community, and their continued failure to do the same in prison is 
in clear opposition to the stated objective of the Prison Medical Service, [T]o provide primary 
health care (prevention, treatment and health rehabilitation) to offenders of at least an equivalent 
standard to that available to citizens in the general community.46 
In the words of UNAIDS, “Whether the authorities admit it or not — and however much they try to 
repress it – drugs are introduced and consumed by inmates in many countries....Denying or 
ignoring these facts will not help solve the problem of the continuing spread of HIV.”47 This is the 
stark reality that the Irish government must face, and act to address. The experience of health 
services in many parts of Ireland, as well as in many prison systems internationally, shows us that 
harm reduction provides the framework for effective action to prevent the transmission of HIV and 
hepatitis C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EXAMPLES OF 
INTERNATIONAL 
BEST PRACTICE 
How does 
Ireland 
compare? 
According to the World Health Organizations’ Guidelines on 
HIV Infection and AIDS in Prisons, “(A)ll prisoners have the 
right to receive health care, including preventative measures, 
equivalent to that available in the community without 
discrimination.”48 Many countries have taken positive steps 
to move towards meeting these guidelines by implementing 
innovative prevention and care programmes. However, the 
Irish Prison Service lags far behind current best practice in 
almost every major area of HIV/AIDS and hepatitis C 
prevention and support. Some of these key areas are 
summarised below. 
Bold initiatives have been undertaken in several European and North American jurisdictions in 
o ss HIV and hepatitis C infection among prisoners. The Irish 
g examples of best practice in prison health care, and make similar 
p le here. 
I aterials 
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 rder to comprehensively addre
overnment must examine these 
rogrammes and services availab
. Condoms and Safer Sex m
ondom use is internationally ac
exual transmission of HIV49. A
risoners as part of their institutio
tudy found that 23 of 52 prison
001, 18 of the 23 prison systemsondom distribution in prisons as part of a comprehensive HIV prevention programme is supported 
y the World Health Organization, and is a key recommendation in two major studies of HIV and 
epatitis C in Irish prisons produced in 1999 and 2000. 
In Ireland... 
The Irish Prisons Service remains one of the last jurisdictions in Europe that does not provide 
condoms to prisoners. 
Recommendation: 
Condoms, dental dams, and water-based lubricants must be made available to all prisoners. 
These materials must be available in a discreet and anonymous fashion that does not 
necessitate making a request to prison staff. 
I. Bleach 
ull-strength bleach may be used to reduce the risk of HIV transmission via the sharing of used 
yringes, as it has the potential to kill the virus if used properly. However, bleach is far from an 
ptimum HIV and hepatitis C prevention measure, as it is less that 100% effective in killing HIV, 
nd is of unknown efficacy against hepatitis C. Still, for injection drug using prisoners who cannot 
ccess sterile syringes, the provision of bleach does provide a useful harm reduction option, and is 
vailable in many prison systems internationally. 
ccording to UNAIDS, the provision of full-strength bleach to prisoners as a harm reduction 
easure has been successfully adopted in prisons in Europe, Australia, Africa, and Central 
merica. The WHO further reports that concerns that bleach might be used as a weapon have 
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proved unfounded, and that this “has not happened in any prison where bleach distribution has been 
tried.”52 
By August 2001, bleach was provided in 11 of 23 EU prison systems.53 In Canada, bleach has been 
available in over twenty prisons in the province of British Columbia since 1992. In 1996, Canada’s 
federal prison system introduced bleach distribution programmes in all fifty-two institutions under 
federal jurisdiction.54 
In April 2000, the Irish Prisons Service introduced disinfectant tablets to the medical unit in 
Mountjoy. However, this project was stopped following objections from the Prison Officers’ 
Association.55 In September 2001, the Report of the Group to Review the Structure and 
Organisation of Prison Health Care Services recommended “disinfectant tablets should be 
introduced in the Irish prison system without further delay.”56 
In Ireland… 
The Irish Prisons Service does not provide bleach to prisoners as a harm reduction measure. 
Recommendation: 
Access to full-strength bleach must be made available to all prisoners. Bleach must be 
available in a discreet and anonymous fashion mat does not necessitate making a request to 
prison staff. 
III. Needle Exchange 
The first prison needle exchange programme was established in the Oberschöngrün maximum 
security prison for men in Switzerland in 1992/93. In June 1994, a second Swiss programme was 
initiated at the Hindelbank institution for women. 
In the Hindelbank project, sterile syringes were accessed from dispensing machines set up in 
various parts of the institution. Prisoners were allowed to possess one syringe, provided it was kept 
in a specially designated cabinet. During the first year of the project, 5,335 syringes were 
distributed to prisoners.57 
At the end of the first year the Hindelbank project was evaluated. The evaluators found that there 
were no new cases of HIV or hepatitis C in the institution, there was an overall improvement in 
prisoners’ health, there was a significant decrease in syringe sharing, there was no increase in 
drug consumption, and there were no instances of syringes being used as weapons.58 
Since that time, needle exchange programmes have been established in a total of nineteen prisons in 
Switzerland, Germany, and Spain.59 A study in Australia has supported the feasibility of prison 
needle exchange, and a working group established by the Correctional Service of Canada has 
recommended the implementation of pilot needle exchange programmes in five Canadian prisons.60 
A 2000 study by Merchants Quay Ireland has demonstrated that needle exchange programmes in 
the community are effective in reducing syringe sharing among injection drug users.61 The Irish 
government’s new National Drugs Strategy. 2001—2008 endorses the importance of needle 
exchange programmes as part of an HIV and hepatitis C prevention strategy, and identifies the need 
“[t]o review the existing network of needle-exchange facilities with a view to ensuring access for all 
injecting drug misusers to sterile injecting equipment.”62 Given that a significant number 
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of injection drug users are incarcerated, the government can only meet this target if they follow 
international best practice and expand needle exchange programmes into prisons. However, 
providing needle exchange to prisoners is not part of the Strategy, despite a recommendation in a 
1999 study of HIV and hepatitis C in Irish prisons that “a strictly controlled supply of clean needles 
and syringes should be available for those prisoners who will continue to inject opiates.”63 
In Ireland… 
The Irish Prisons Service does not provide sterile injecting equipment to prisoners. 
Recommendation: 
Access to sterile injecting equipment must be made available to all prisoners. This equipment 
must be available in a discreet and anonymous fashion that does not necessitate making a 
request to prison staff. The Irish government should investigate the several models of needle 
exchange programmes currently in operation in various European prisons as a guide. 
IV. Methadone Maintenance 
Methadone maintenance is used internationally as an effective replacement therapy for opiates, and 
an important harm reduction option for injection heroin and morphine users. Administered orally, 
methadone allows injection opiate users an option for ending their reliance on illegal drugs, and to 
cease injecting practices. As such, methadone forms an important part of harm reduction 
programmes in many countries, including Ireland. 
During the 1990s, methadone programmes were widely introduced in prisons in Europe and 
Canada. In September 2001, the Correctional Service of Canada (CSC) published an evaluative 
study on their methadone programme, which concluded that participation in methadone 
programmes had positive post-release outcomes.64 The study found that opiate users accessing 
methadone maintenance therapy (MMT) during their incarceration were less likely to be readmitted 
to prison following their release – and were less likely to have committed new offences – than were 
those not accessing methadone. The study further concluded that 
an important implication of these findings is that CSC may spend less money on 
these offenders in the long term. The cost of the institutional MMT program may be 
offset by the cost savings of offenders successfully remaining in the community for a 
longer period of time than equivalent offenders not receiving MMT. In addition, 
health related costs such as treatment for HIV or Hepatitis C infection would be 
affected by MMT availability in prisons65 
In 2000, the Irish Prisons Service introduced methadone into several Dublin prisons. This was an 
important decision by the Prisons Service, as it recognized the scope of injection drug use within 
the prison system, and the value of harm reduction programmes. 
However, the current system falls far short of the comprehensive response necessary to address the 
problem of HIV and hepatitis C transmission through injection heroin use. At present, methadone is 
only available in Dublin prisons, which means that half of Irish prisoners cannot access the 
treatment by virtue of the region in which they are imprisoned. In addition, only those prisoners 
who are prescribed methadone prior to incarceration qualify to avail of the programme. Rarely are 
prisoners authorised to initiate methadone while they are incarcerated, Methadone is thereby 
eliminated as an option for the majority of opiate-using prisoners. For heroin using 
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prisoners who are infected with hepatitis C, the inability to initiate methadone therapy while 
incarcerated can create significant barriers to initiating hepatitis C treatment. 
In the words of the Prison Officers’ Association – who has been highly critical of the limitations of 
the current methadone policy – this policy has created “a two-tier prison system and is totally 
unacceptable.”66 
In Ireland... 
Methadone is provided on a limited basis in Dublin area prisons, and only to those individuals 
on a methadone programme prior to incarceration. Prisoners are rarely able to initiate 
methadone therapy while incarcerated. 
Recommendation: 
The recent decision by the Irish Prisons Service to implement methadone maintenance in 
Dublin prisons is to be commended. However, methadone maintenance must be expanded to 
all institutions in all regions, and made accessible to all medically qualifying prisoners. The 
methadone programme must also be expanded to allow medically qualifying prisoners to 
initiate methadone therapy while in prison. 
V. Care, Treatment, and Support. 
HIV/AIDS and hepatitis C are chronic or fatal illnesses for which no cure or vaccine currently 
exists. Both require ongoing monitoring of disease progression, and access to specialist medical 
intervention, drug therapies, and pain management. Both require access to proper diet and nutrition 
as a health promotion strategy.67 
Providing a proper standard of care, treatment, and support for people living with HIV/AIDS and/or 
hepatitis C is not simply an issue of service delivery. It is a central component of an holistic and 
comprehensive health strategy. According to the World Health Organization/ UNAIDS, “[a]ccess 
to care and support... contributes to the prevention of HIV infection” and “decreases the spread of 
infectious diseases that are common among HIV-infected people.”68 Providing adequate care and 
support also contributes to enhancing the environment in which people live and in which prevention 
education initiatives take place. “By caring openly and compassionately for HIV infected people, 
the care-givers alleviate community’s fear of HIV infection, and alleviate stigma and 
discrimination.”69 
In order to provide comprehensive and accessible care and treatment for prisoners living with 
HIV/AIDS and/or hepatitis C, it is essential that consistent and accessible medical services be 
available in all institutions, provided by fully trained and certified health care professionals. 
However, this is not the case in Irish prisons, where primary health care services are provided by 
GPs contracted on only a part-time basis, and many nursing services are not provided by trained 
nurses but by medical orderlies – prison officers with only basic first aid training. 
To address this inadequacy in the provision of prison medical services, the 2000 General Healthcare 
Study of the Prisoner Population recommended 
the introduction of an adequately funded comprehensive primary care health 
service across the prison system…..This would mean that doctors and other health 
care staff would be available on a full time basis in larger institutions on the same 
per capita arrangement as a GMS (General Medical Service) list.70       
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In the case of HIV/AIDS care, existing barriers are exacerbated by disparities in regional health care 
infrastructure. In Ireland, the majority of physicians specialising in HIV/AIDS are located in 
Dublin. Therefore, specialised HIV/AIDS care is less available to prisoners incarcerated outside of 
the Dublin region. While this is not a fault of the Prisons Service, it is an issue the Service must take 
into account in designing an HIV/AIDS and hepatitis C strategy. 
There are currently no “hospital” facilities within Irish prisons, and those prisoners requiring more 
intensive care are transferred to outside hospitals, typically under security escort.71 While a 
“medical unit” does exist in Mountjoy, it has recently been described as “unsuitable for most 
medical purposes.”72 Many prisoners living with HIV/AIDS are housed in this unit in Mountjoy. 
The lack of proper hospital facilities and consistent access to specialist care within the Irish prison 
system is a concern for all prisoners. However, it has particular impact on those with chronic and 
life-threatening illnesses such as HIV/AIDS and hepatitis C, as the risk of severe health decline 
requires ongoing medical attention, and can make it difficult or impossible for them to live 
comfortably within normal prison units. 
To address such systemic barriers in providing health services to prisoners, some jurisdictions have 
opted to remove health care responsibilities from the prison system altogether. According to 
UNAIDS, “Experience in a range of prison systems has shown that health care in prisons can be 
delivered more effectively by public health authorities than by prison management.”73 The prison 
systems in Norway and France have both adopted this model,74 as have several prisons in the 
province of Québec in Canada. 
Calls to transfer the responsibility for correctional medical care outside of the Prisons Service have 
been made here in Ireland. A 1999 study of HIV and hepatitis C in prisons concluded, “it would be 
better...if ultimate responsibility for the prison health service rested with the Department of Health 
and Children.”75 A related study in 2000 recommended that “[h]ealth services [be] provided by an 
independent multidisciplinary team.”76 
In Ireland... 
Primary medical services are provided by GPs contracted on a part-time basis. Nursing 
services are primarily provided by medical orderlies who have no formal medical training or 
certification. Specialist medical services for prisoners living with HIV/AIDS are concentrated 
in Mountjoy Prison in Dublin. 
Recommendations: 
• Access to adequately funded, comprehensive medical services must be consistent across 
the country and among institutions. Adequately staffed and resourced health units must be 
developed in all institutions. 
• We support the finding of the General Healthcare Study of the Prisoner Population, 
which recommends “that doctors and other health care staff….be available on a full time basis 
in larger institutions, on the same per capita arrangement as a GMS (General Medical Service) 
list.” 
• Mentoring relationships should be established between HIV/AIDS and hepatitis C 
specialist consultants in Dublin and GPs providing primary care services in the various 
regional institutions in order to support them in providing care to prisoners living with 
HIV/AIDS and/or hepatitis C. 
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• The Irish Prisons Service’s commitment to hire professionally qualified nursing staff is 
to be commended. This process must proceed on schedule, and result in properly qualified 
nursing staff in all institutions. 
• Increased resources must be dedicated, and ongoing training provided, to health care 
staff in all institutions to enable them to meet the unique and evolving needs of prisoners on 
HIV and/or hepatitis C therapies. 
• Prisoners living with HIV/AIDS and/or hepatitis C must be provided equal and non-
discriminatory access to pain management medications. 
• Prisoners living with HIV/AIDS and/or hepatitis C must have access to proper and 
sufficient nutrition, including vitamin supplements and supplement drinks. For those prisoners 
on medications, diet and mealtimes must be adapted to meet the requirements of the drug 
therapies. 
VI. Confidentiality and Testing 
Confidentiality is often the single biggest concern for prisoners living with HIV/AIDS. It is also a 
concern for those infected with hepatitis C. 
Prisoners are entitled to the same confidentiality of their medical information as people in the 
general community. However, confidentiality is often inadvertently compromised or deliberately 
breached within the prison environment by staff and prisoners alike.77 The fact that prison medical 
orderlies are themselves prison officers also contributes to a general lack of confidence among 
prisoners in the security of medical information. 
The resulting lack of trust has important implications for an HIV/AIDS and hepatitis C strategy. 
Because of the significant social stigma attached to HIV and hepatitis C, fears about the 
confidentiality of medical information affects participation in health services. This lack of 
confidence acts as a deterrent to testing, to accessing medical care, and even to availing of 
educational materials and information. For this reason, improving systems and practices for 
maintaining confidentiality – and building trust in the security of medical information among the 
prison population – must be a central component of an effective HIV and hepatitis C strategy. 
Confidentiality is a particularly crucial element of an effective HIV and hepatitis C testing protocol. 
Unless prisoners themselves have trust in the privacy of their test results, many will choose not to 
avail of existing testing services. Pre- and post-test counselling for those being tested is an 
important element of best practice in this regard. According to the World Health 
Organization/UNAIDS, 
Testing should be voluntary and confidential, and should be accompanied by counselling. 
Counselling is important to prepare clients to come to terms with their HIV status: this 
includes dealing with fear, guilt, stigma, discrimination, care for a chronic condition, the 
possibility of early death, and to give them an understanding of what they can and should 
do about HIV infection, should they be HIV-infected. It is also important in helping people 
devise or strengthen ways of staying HIV negative, if they test HIV negative.78 
In several Canadian jurisdictions, “anonymous” HIV testing is available. Anonymous testing has 
been provided in several prisons in Quebec and Saskatchewan since the mid-1990s. In these 
institutions, testing is provided by outside community health agencies that come into the prison 
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on a regular basis to provide the service. The use of outside health workers, rather than prison staff, 
is done in order to increase trust in the confidentiality of the service among the prison population, 
and reduce fears that results will be shared with the institution. Pre- and post-test counselling is 
standard, and the test results are provided only to the prisoners, and not shared with the prison. 
Based upon the success of these projects, the Canadian federal prison system is currently pilot 
testing similar programmes in two penitentiaries, with an eye to making anonymous testing 
available in all federal institutions across the country. 
In Ireland... 
HIV and hepatitis C testing is provided on request to prisoners. Pre- and post-test counselling 
is unevenly practiced. 
Recommendations: 
• Confidential HIV and hepatitis C testing must be made accessible for all prisoners. 
• Pre- and post-test counselling must be a mandatory component of HIV and hepatitis C 
testing practices. 
• We welcome plans by the Prisons Service to increase security of prisoner medical 
information. 
• Breaches of confidentiality by employees of the Prisons Service are unprofessional and 
unacceptable. Ongoing support and education for staff should be provided in an effort to 
constantly improve institutional confidentiality practices. All breaches of confidentiality by 
staff should be investigated, and appropriate disciplinary sanctions imposed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RECOMMENDATIONS 
HIV/AIDS 
& Hepatitis C 
in Prisons 
Based upon these findings, the Irish Penal Reform Trust 
and Merchants Quay Ireland make the following 
Recommendations. 
 
Our Recommendations are based upon the following core principles. 
• Prisoners have the right to protect themselves from HIV and hepatitis C infection. 
• Prisoners have the right to informed consent in regards to medical treatments, including the 
right to refuse treatment. 
• Prisoners have a right to confidentiality regarding their HIV and hepatitis C status. 
• Prisoners have the right to informed consent in regards to HIV and hepatitis C testing, 
including the right to refuse testing. 
• No prisoner should be segregated based upon HIV or hepatitis C status. 
• No one should be allowed to die in prison from HIV/AIDS or hepatitis C. 
Our Recommendations are also based on the belief that reducing the prevalence of disease and 
illness within prison walls is to the benefit of everyone in the prison community, including 
prisoners, staff members, friends, and family members. 
Prevention and Education. 
We recommend that: 
1. Condoms, dental dams, and water-based lubricants must be made available to all prisoners. 
2. Access to sterile injecting equipment must be made available to all prisoners. 
3. Access to full-strength bleach must be made available to all prisoners. 
4. The current methadone maintenance programme must be expanded to all institutions in all 
regions, and made accessible to all medically qualifying prisoners. 
5. Personal hygiene items, particularly razors, toothbrushes, and nail clippers, must be 
individually available to every prisoner. 
6. The Prisons Service should investigate strategies to reduce the transmission of HIV and 
hepatitis C infection via tattooing practices. 
7. Comprehensive, accurate, and appropriate HIV/AIDS and hepatitis C prevention education 
must be made mandatory for all prisoners and prison staff. Funding should be provided so 
that community-based organisations can increase their role in providing this service, rather 
than having the responsibility fall to prison staff alone. 
8. All prison staff must receive mandatory and ongoing training on the use of universal 
precautions as a standard part of proper workplace safety and practice. 
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Care, Treatment, and Support. 
We recommend that: 
1. Access to adequately funded, comprehensive medical services must be consistent across the 
country and among institutions. Adequately staffed and resourced health units must be 
developed in all institutions. 
2. We support the finding of the General Healthcare Study of the Prisoner Population, which 
recommends “that doctors and other health care staff...be available on a full time basis in 
larger institutions on the same per capita arrangement as a GMS (General Medical Service) 
list.” 
3. Mentoring relationships should be established between HIV/AIDS and hepatitis C specialist 
consultants in Dublin and GPs contracted to provide primary care services in the various 
regional institutions, in order to assist them in providing care to prisoners living with 
HIV/AIDS and/or hepatitis C. 
4. The Irish Prison Service’s commitment to hire professionally qualified nursing staff is to be 
commended. This process must proceed on schedule, and result in adequate levels of 
properly qualified nursing staff in all institutions. 
5. Increased resources must be dedicated, and ongoing training must be provided, to health care 
staff in all institutions to enable them to meet the unique and evolving needs of prisoners 
living with HIV/AIDS and/or hepatitis C. 
6. Prisoners living with HIV/AIDS and/or hepatitis C must be provided equal and non-
discriminatory access to pain management medications. 
7. Prisoners living with HIV/AIDS and/or hepatitis C must have access to proper and sufficient 
nutrition, including vitamin supplements and supplement drinks. For those prisoners on 
medications, diet and mealtimes must be adapted to meet the requirements of the drug 
therapies. 
8. Community-based health organisations must be facilitated in providing HIV/AIDS and 
hepatitis C support and health promotion to prisoners. Increased financial resources must be 
made available to community-based organisations for this purpose. 
9. Compassionate release provisions for prisoners living with HIV/AIDS and/or hepatitis C 
should be exercised proactively, and earlier in the course of disease progression. 
Confidentiality and Testing. 
We recommend that: 
1. Confidential HIV and hepatitis C testing must be made easily accessible for all prisoners. 
2. Pre- and post-test counselling must be a mandatory component of HIV and hepatitis C 
testing. 
3. We welcome plans by the Prisons Service to increase security of prisoner medical 
information. 
4. Breaches of confidentiality by employees of the Prisons Service are unprofessional and 
unacceptable. Ongoing support and education for staff should be provided in an effort to 
constantly improve institutional confidentiality practices. All breaches of confidentiality by 
staff should be investigated, and appropriate disciplinary sanctions imposed. 
CONCLUSION 
A Call 
for Action 
Everyone has the right to access preventive health care and the right 
to benefit from medical treatment under the conditions established by 
national laws and practice79. 
Charter of Fundamental Rights of the European Union 
Article 35 
 
 
HIV/AIDS and hepatitis C are challenging issues for prison systems. 
Epidemic rates of infection among prisoners have challenged governments to act. Yet implementing 
the measures and programmes known to be effective has also challenged the conventional thinking 
of many prison bureaucracies, prison staff, and the public at large. Prison systems have struggled 
with the idea that programmes such as condom distribution and needle exchange have a place in the 
prison environment. In Ireland, these challenges are the same. However, international experience 
and best practice have demonstrated that these services and others are not only appropriate, they are 
in fact an essential part of a comprehensive health response to HIV and hepatitis C. 
It is an unfortunate truth that negative public attitudes towards prisoners often act as a barrier to 
objective discussions of prison policy. Yet sound health policy is never based upon prejudice. It is 
based upon need, and on effective and evaluated models of service delivery. On these criteria, the 
demand for the implementation of a comprehensive HIV/AIDS and hepatitis C prevention and 
support strategy in Irish prisons is clear. 
While sound health policy is never based upon prejudice, it is often obstructed or delayed by it. 
Therefore, implementing an effective health policy in Irish prisons demands leadership from 
government, and the willingness to act in the best interests of public health. Indeed, the government 
has the responsibility to act. This responsibility is articulated in international guidelines set by the 
World Health Organization and UNAIDS, and in Article 35 of the Charter of Fundamental Rights 
of the European Union. 
To date, the Irish Prisons Service has been slow to act in the innovative and comprehensive manner 
of other jurisdictions. While this delay is regrettable, the Prisons Service now has the opportunity to 
learn from the ground-breaking efforts of other prison systems, and act quickly to implement the 
types of health services that have been proven effective in other countries. 
International experience has shown the advantages when prison staff, community-based HIV/AIDS 
organisations, medical experts, and prisoners work together to address these often complex health 
issues. It has also shown the dangers of failing to act in the face of this health crisis. 
The Irish Penal Reform Trust and Merchants Quay Ireland look forward to making our contribution 
to the collective effort to improve health services for prisoners. We invite the Prisons Service to 
work with us and other community stakeholders to implement a comprehensive and compassionate 
response to HIV/AIDS and hepatitis C in Irish prisons. 
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